| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.76B | 6.58B | 6.49B | 5.94B | 4.97B | 4.29B |
| Gross Profit | 935.00M | 1.05B | 1.04B | 1.01B | 820.10M | 806.85M |
| EBITDA | 98.00M | 198.00M | 295.00M | 300.29M | 214.32M | 228.47M |
| Net Income | 17.00M | 91.00M | 171.00M | 179.35M | 124.08M | 138.24M |
Balance Sheet | ||||||
| Total Assets | 2.01B | 2.60B | 2.12B | 2.04B | 1.75B | 1.58B |
| Cash, Cash Equivalents and Short-Term Investments | 519.00M | 1.05B | 709.00M | 765.90M | 607.60M | 589.38M |
| Total Debt | 436.00M | 435.00M | 427.00M | 424.99M | 433.59M | 433.69M |
| Total Liabilities | 1.93B | 2.50B | 2.03B | 1.96B | 1.75B | 1.54B |
| Stockholders Equity | 87.00M | 97.00M | 94.00M | 81.28M | -1.77M | 44.13M |
Cash Flow | ||||||
| Free Cash Flow | 51.00M | 482.00M | 158.37M | 317.36M | 227.25M | 248.19M |
| Operating Cash Flow | 86.00M | 520.00M | 198.49M | 347.69M | 260.15M | 346.35M |
| Investing Cash Flow | -35.00M | -38.00M | -21.73M | -32.12M | -31.01M | -98.62M |
| Financing Cash Flow | -111.00M | -173.00M | -155.01M | -141.15M | -208.07M | -53.58M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $3.56B | 13.85 | 13.89% | 2.81% | 3.65% | 5.71% | |
66 Neutral | $935.55M | 17.53 | 24.08% | 0.88% | 9.64% | 9.93% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
60 Neutral | $2.83B | 18.13 | 11.27% | 8.45% | -7.27% | -43.88% | |
58 Neutral | $2.80B | 21.28 | 111.30% | 1.81% | 0.99% | -47.02% | |
54 Neutral | $1.46B | 87.29 | 16.04% | 6.22% | 3.19% | -86.21% | |
54 Neutral | $1.38B | -63.65 | -1.00% | 4.82% | -2.44% | -156.01% |
On December 15, 2025, Insperity, Inc. announced an Eighth Amendment to its Amended and Restated Credit Agreement with Zions Bancorporation, N.A. dba Amegy Bank and other lenders. This amendment increases the borrowing capacity under its revolving credit facility from $650 million to $750 million, with a potential increase to $800 million, extends the maturity date to December 15, 2028, and adjusts financial covenants, potentially enhancing Insperity’s financial flexibility and operational capacity.
On November 3, 2025, Insperity announced an amendment to its arrangement with UnitedHealthcare, extending the contract through 2028 and introducing cost-saving measures starting in 2026. This strategic move is expected to enhance Insperity’s financial outlook and align with its growth and profitability goals. Additionally, Insperity reported its third-quarter results, highlighting a 4% revenue increase despite a net loss of $20 million due to elevated healthcare costs. The company is actively working on sustainable profitability and has launched HRScale, a joint solution with Workday, to strengthen its market position.